StockDuty ← Dashboard Oct 25, 2026 07:07 PM ET
SignalFDA/Bio

Summit Therapeutics reports a survival benefit for its cancer drug in a trial. Survival is the endpoint that matters most in oncology, so this is the line the tape will trade around. $SMMT

Summit Therapeutics reports survival benefit for cancer drug in trial.

SMMT
$14.15
-6.14%
Summit Therapeutics reports survival benefit for cancer drug in trial.
Summit Therapeutics reports survival benefit for cancer drug in trial. — impact context not separately stored; see What changed.
Sources